Steering Committee 
Robert W. Hallowell, MD
Assistant Professor of Medicine 
Harvard Medical School
Director, Interstitial Lung Disease Program
Pulmonary Clinic Director
Division of Pulmonary, Critical Care and Sleep Medicine 
Massachusetts General Hospital 
Boston, MA

Kristin B. Highland, MD
Director, Rheumatic Lung Disease Program
Cleveland Clinic 
Cleveland, OH

Elizabeth R. Volkmann, MD, MS
Assistant Professor of Medicine
Director, UCLA Scleroderma Program
Co-Director, UCLA CTD-ILD Program
Division of Rheumatology
Department of Medicine
University of California, Los Angeles 
David Geffen School of Medicine
Los Angeles, CA
This activity is provided by Paradigm Medical Communications, LLC. 

This activity is held in collaboration with the Pulmonary Fibrosis Foundation. 

Disclosure of Financial Support
This activity is supported by an educational grant from Genentech, a member of the Roche Group. 

Target Audience
This activity has been designed to address the educational needs of academic and community-based pulmonologists and rheumatologists. It may also benefit pathologists, radiologists, dermatologists, primary care physicians, nurse practitioners, PAs, pharmacists, nurses, residents, fellows, and other healthcare professionals involved in the care of patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD).

Statement of Need
Scleroderma or systemic sclerosis (SSc) is a rare autoimmune disorder characterized by fibrosis in the skin and internal organs, including the lungs, that results in increased morbidity and mortality for patients. SSc-ILD occurs in the majority of patients. Due to the rarity of the disease and the heterogeneity of symptoms, patients often experience diagnostic delay until referral to an appropriate specialist, thus delaying the opportunity for early treatment. For patients with risk factors for severe interstitial lung disease (ILD), rapid progression often occurs within the first 5 years from diagnosis. There is no curative treatment for SSc, but immunosuppressive agents, including the most recently approved, tocilizumab, and antifibrotics are available to delay the progression of SSc-ILD. Clinicians need to recognize the risk factors for severe SSc-ILD in patients with SSc and perform appropriate baseline testing and ongoing monitoring for ILD; patients presenting with symptoms of ILD need appropriate screening to make an appropriate diagnosis of SSc-ILD, so that therapy can be initiated. Data for the newest agents need to be disseminated and discussed by clinicians to establish the roles of these agents in the treatment of SSc-ILD. Clinicians in regions with centers of excellence need to stay up to date with rapidly emerging data, and clinicians in communities further removed from these centers need to be knowledgeable of SSc-ILD and centers of excellence to refer patients for cutting-edge care.

Learning Objectives
Upon completion of this activity, participants should be able to:

• Assess patient risk factors for progressive SSc-ILD
• Describe recommended monitoring for patients with scleroderma and SSc-ILD
• Develop appropriate, evidence-based treatment plans for patients who have SSc-ILD
• Summarize data on emerging agents for the treatment of SSc-ILD

Agenda
Clinical Program

• Introduction 
• Diagnosis
• Treatment of SSc-ILD       

Physician Accreditation Statement
Paradigm Medical Communications, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physician Credit Designation Statement
Paradigm Medical Communications, LLC designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

PA Continuing Education
PAs may claim a maximum of 1.0 Category 1 credit for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. 

Nurse Practitioner Continuing Education
The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Individuals are responsible for checking with their respective boards for further guidelines.

CME Inquires: For questions regarding CME credit, contact the Paradigm CME Department at (845) 398-5949 or cme@paradigmmc.com.

There is no fee required for participation in this activity.

Disclosures
In accordance with ACCME requirements on disclosure, faculty and contributors are asked to disclose any relationships with ineligible companies associated with the area of medicine featured in the activity. These relationships are described below. Any potential conflicts of interest have been mitigated.

Robert W. Hallowell, MD
Consulting Fees: Boehringer Ingelheim Pharmaceuticals, Inc
Speakers Bureau: Boehringer Ingelheim Pharmaceuticals, Inc
Grant/Research Support: Boehringer Ingelheim Pharmaceuticals, Inc; Regeneron Pharmaceuticals, Inc

Kristin B. Highland, MD
Consulting Fees: Actelion Pharmaceuticals US, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc; Genentech Inc.; United Therapeutics Corporation 
Speakers Bureau: Actelion Pharmaceuticals US, Inc.; Bayer Corporation; Janssen Pharmaceuticals, Inc
Grant/Research Support: Acceleron Pharma; Bayer Corporation; Boehringer Ingelheim Pharmaceuticals, Inc; Gossamer Bio, Inc.; Viela Bio, Inc. 

Elizabeth R. Volkmann, MD, MS
Consulting Fees: Boehringer Ingelheim Pharmaceuticals, Inc
Grant/Research Support: Corbus Pharmaceuticals Holdings, Inc.; Forbius (recently acquired by Bristol-Myers Squibb Company); Kadmon Holdings, Inc.

Paradigm Medical Communications, LLC staff members have no financial relationships to disclose.

Independent peer reviewer has no financial relationships to disclose.

Resolution of Conflict of Interest
Paradigm Medical Communications, LLC has implemented a system to resolve conflicts of interest for each CME activity to help ensure content is objective, fair and balanced, independent, and aligned with the public interest. Conflicts, if any, are resolved through one or more processes. All CME content in this activity was independently reviewed to ensure that it is free of commercial bias, scientifically rigorous, aligned with the public interest, and compliant with all regulatory guidance and the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the FDA.

Disclaimer
This CME activity represents the views and opinions of the individual faculty, and does not constitute the opinion or endorsement of, or promotion by, Paradigm Medical Communications, LLC. Reasonable efforts have been taken to present educational subject matter in a balanced, unbiased fashion, and in compliance with regulatory requirements. However, each activity participant must always use his or her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.

If included, signed statements of informed consent granting permission for publication have been obtained for all photographs and videos in which an individual can be identified.

As an ACCME-accredited provider, Paradigm Medical Communications, LLC’s activities must include a balanced view of therapeutic options. Use of generic names contributes to this impartiality. The use of trade names should not be viewed as an endorsement of specific products by Paradigm Medical Communications, LLC. 

© 2021 Paradigm Medical Communications, LLC except where noted. Content may not be reproduced in whole or part without the express written permission of Paradigm Medical Communications, LLC.